Navigation Links
UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation
Date:7/28/2014

DALLAS July 28, 2014 UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors.

The molecule, SML-8-73-1 (SML), interferes with the KRAS gene, or Kirsten rat sarcoma viral oncogene homolog. The gene produces proteins called K-Ras that influence when cells divide. Mutations in K-Ras can result in normal cells dividing uncontrollably and turning cancerous. These mutations are particularly found in cancers of the lung, pancreas, and colon. In addition, people who have the mutated gene are less responsive to therapy.

Researchers have unsuccessfully tried to develop a drug to inhibit K-Ras for some 30 years.

"RAS proteins including KRAS have not been 'druggable' for many decades despite a lot of effort from academia and industry," said senior author Dr. Kenneth Westover, Assistant Professor of Radiation Oncology and Biochemistry, and a member of UT Southwestern's Harold C. Simmons Cancer Center.

"We are exploring irreversible inhibitors as a solution, which we believe may pave the way for the development of KRAS-targeted compounds with therapeutic potential and perhaps compounds that target other RAS family proteins involved in cancer," Dr. Westover said.

Dr. Westover works as both a clinician as a member of the Lung Radiation Oncology Team at the Simmons Cancer Center, and as a researcher. The Westover laboratory investigates the molecular basis of cancer with an eye toward developing compounds that perturb cancer biology, and therefore have potential to become therapies. Dr. Westover's lab has been particularly targeting KRAS because this gene is the most commonly mutated oncogene in cancer.

Building on previous work, Dr. Westover and fellow investigators used a technique called X-ray crystallography to determine what happens when SML is added to KRAS carrying the G12C mutation, a hallmark of tobacco-associated lung cancer and present in 25,000 of the new cases of lung cancer in the U.S. annually.

Researchers found that SML irreversibly binds to mutated KRAS, making the KRAS G12C inactive. SML competes with molecules that KRAS naturally binds to, called GTP and GDP, and is not removable, even when GTP and GDP are present at very high levels. This attribute is what makes SML an irreversible inhibitor neither GDP nor GTP are able to knock it off and take its place.

The researchers then used a technique called mass spectrometry to determine that SML is not only irreversible, but selective binding only to KRAS and not the roughly 100 other members of the RAS protein family that have very similar structures.

"We believe SML may be the first irreversible and selective inhibitor of KRAS," said Dr. Westover, who was recruited to UT Southwestern with funds from the state-funded Cancer Research and Prevention Institute of Texas. "As a next step, we are improving the SML compound to facilitate studies involving living cancer cells, and eventually animals and humans."


'/>"/>

Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Study helps compare risks of treatments for early esophageal cancer
2. Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors
3. Potential universal blood test for cancer discovered
4. Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills
5. Lifestyle choices may affect the long-term heart health of childhood cancer survivors
6. Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk
7. Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening
8. Anal, Throat Cancers on the Rise Among Young Adults, Study Finds
9. Scientists test nanoparticle alarm clock to awaken immune systems put to sleep by cancer
10. ACR statement on cancer study regarding patient anxiety from CT lung cancer screening
11. Is Europe putting cancer research at risk?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... London, ... was honored to serve earlier this month as a Guest Speaker and Contributor to ... British Royal Family and Common Purpose. , Walter Schindler and ...
(Date:5/23/2017)... ... May 23, 2017 , ... By all indications, and due to months ... officials call for diligence, asking homeowners to scout for any open water sources that ... with the annoying buzz of mosquitos is the buzz associated with potential infections stemming ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech ... in the modern ART laboratory, to provide hands-on training utilizing cutting-edge equipment at ... NextGen LifeLabs, a MedTech Group Purchasing vendor , will provide specialized equipment ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, SC, are ... dentist practicing in Mt. Pleasant, SC, with or without a referral. A full mouth ... with missing teeth in Charleston, SC. Those who suffer from gum disease, ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... New ... gums and chronic bad breath, can now receive laser gum disease treatments from the ... Douglas Campbell and David Landau are raising awareness of the importance of receiving qualified ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)...  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... focused on the development of oral drug delivery ... Office has granted Oramed a patent titled, "Methods ... patent covers Oramed,s invention of an oral glucagon-like ... incretin hormone that stimulates the secretion of insulin ...
(Date:5/6/2017)... IRVING, Texas , May 5, 2017   Provista ... 1994 with more than 200,000 customers, today announced Jim ... brings a wealth of executive and business experience to Provista, ... a compounding pharmacy in California . He ... "Jim is a great fit for Provista," says ...
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
Breaking Medicine Technology: